Informations:
Erreur:
ID
16741
Description
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00061815
Lien
https://clinicaltrials.gov/show/NCT00061815
Mots-clés
Versions (1)
- 03/08/2016 03/08/2016 -
Téléchargé le
3 août 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Colorectal Cancer NCT00061815
Eligibility Colorectal Cancer NCT00061815
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Cancer NCT00061815
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Colorectal cancer metastatic Epidermal Growth Factor Receptor Positive
Item
documented colorectal cancer which is egfr-positive and is metastatic.
boolean
C0948380 (UMLS CUI [1,1])
C0034802 (UMLS CUI [1,2])
C1446409 (UMLS CUI [1,3])
C0034802 (UMLS CUI [1,2])
C1446409 (UMLS CUI [1,3])
irinotecan | First line treatment Neoplasm Metastasis
Item
prior irinotecan, alone or in combination, as first-line treatment of metastatic disease.
boolean
C0123931 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0027627 (UMLS CUI [2,2])
C1708063 (UMLS CUI [2,1])
C0027627 (UMLS CUI [2,2])
Disease Uncontrolled Serious Impairing Protocol Compliance
Item
a serious uncontrolled medical disorder that, in the opinion of the investigator, would impair the ability of the subject to receive protocol therapy.
boolean
C0012634 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C0221099 (UMLS CUI [1,4])
C0525058 (UMLS CUI [1,5])
C0205318 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C0221099 (UMLS CUI [1,4])
C0525058 (UMLS CUI [1,5])
Dihydropyrimidine Dehydrogenase Deficiency
Item
known dihydropyrimidine dehydrogenase (dpd) deficiency.
boolean
C1959620 (UMLS CUI [1])
CNS metastases
Item
known metastases in the central nervous system.
boolean
C0686377 (UMLS CUI [1])
Sensory neuropathy Symptomatic | Peripheral Neuropathy Symptomatic
Item
symptomatic sensory or peripheral neuropathy.
boolean
C0151313 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0031117 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C0231220 (UMLS CUI [1,2])
C0031117 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Prior Chemotherapy Quantity Colorectal cancer metastatic
Item
more than one prior chemotherapy regimen for the treatment of metastatic colorectal cancer.
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0948380 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0948380 (UMLS CUI [1,3])
oxaliplatin
Item
prior oxaliplatin therapy.
boolean
C0069717 (UMLS CUI [1])
cetuximab Targeting Epidermal Growth Factor Receptor Pathway | Therapeutic procedure Targeting Epidermal Growth Factor Receptor Pathway
Item
prior cetuximab or other therapy which targets the egf pathway.
boolean
C0995188 (UMLS CUI [1,1])
C1521840 (UMLS CUI [1,2])
C2984382 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984382 (UMLS CUI [2,3])
C1521840 (UMLS CUI [1,2])
C2984382 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984382 (UMLS CUI [2,3])
Monoclonal Antibody Therapy chimeric | Monoclonal Antibody Therapy Murine
Item
prior chimerized or murine monoclonal antibody therapy.
boolean
C0279694 (UMLS CUI [1,1])
C0598622 (UMLS CUI [1,2])
C0279694 (UMLS CUI [2,1])
C0026809 (UMLS CUI [2,2])
C0598622 (UMLS CUI [1,2])
C0279694 (UMLS CUI [2,1])
C0026809 (UMLS CUI [2,2])